However, conclusive evidence is still missing regarding whether PCSK9 inhibitors reduce ASCVD risk specifically through Lp(a) reduction, or if the observed benefits are primarily due to achieving much lower LDL-C levels. Here, PCSK9 is linked to atherosclerosis.